NASDAQ:PACB - Nasdaq - US69404D1081 - Common Stock - Currency: USD
Taking everything into account, PACB scores 2 out of 10 in our fundamental rating. PACB was compared to 54 industry peers in the Life Sciences Tools & Services industry. PACB has a bad profitability rating. Also its financial health evaluation is rather negative. PACB is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -76.41% | ||
ROE | -717.77% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.49% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 7.05 | ||
Debt/FCF | N/A | ||
Altman-Z | -5.35 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 6.68 | ||
Quick Ratio | 5.87 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:PACB (7/24/2025, 1:21:07 PM)
1.54
-0.15 (-8.88%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 3.03 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 5.04 | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -76.41% | ||
ROE | -717.77% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.49% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 7.05 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 2.16% | ||
Cap/Sales | 5.71% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 6.68 | ||
Quick Ratio | 5.87 | ||
Altman-Z | -5.35 |